<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-0255</journal-id>
<journal-title><![CDATA[Revista Archivo Médico de Camagüey]]></journal-title>
<abbrev-journal-title><![CDATA[AMC]]></abbrev-journal-title>
<issn>1025-0255</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-02552018000400468</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización de los patrones de prescripción de nuevos antiepilépticos]]></article-title>
<article-title xml:lang="en"><![CDATA[Prescription patterns characteristics of new antiepileptic drugs]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Arias]]></surname>
<given-names><![CDATA[Tania]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Gutiérrez]]></surname>
<given-names><![CDATA[Indira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Don Quirós]]></surname>
<given-names><![CDATA[Emilia Argelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Rodríguez]]></surname>
<given-names><![CDATA[Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mederos Pérez]]></surname>
<given-names><![CDATA[Iraida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Morales]]></surname>
<given-names><![CDATA[Marena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Camagüey  ]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<volume>22</volume>
<numero>4</numero>
<fpage>468</fpage>
<lpage>485</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-02552018000400468&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-02552018000400468&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-02552018000400468&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: la epilepsia es una de las enfermedades neurológicas más frecuentes y cerca del 30 % de los pacientes que la padecen no se controlan con antiepilépticos clásicos.  Objetivo:  caracterizar los patrones de prescripción de antiepilépticos nuevos en el municipio Camagüey.  Métodos:  se realizó un estudio descriptivo transversal de utilización de medicamentos, de tipo prescripción/indicación, con elementos de esquema terapéutico. El universo estuvo constituido por 300 pacientes y todos quedaron incluidos en el estudio. Las variables evaluadas fueron: grupo de edad, indicaciones, asociaciones e intervalos de administración.  Resultados: predominó el uso de vigabatrina y lamotrigina en niños y en pacientes con diagnóstico de epilepsia, mientras que la gabapentina se empleó más en adultos y en el dolor neuropático. La vigabatrina y la lamotrigina se emplearon sobre todo asociadas a antiepilépticos clásicos, donde el valproato fue el más utilizado. La gabapentina se utilizó sólo en monoterapia. Existieron errores en los intervalos de administración de los tres fármacos estudiados.  Conclusiones: la prescripción de nuevos antiepilépticos fue adecuada en la mayoría de los casos. Los errores identificados estuvieron relacionados con los intervalos de administración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: epilepsy is one of the most frequent neurological diseases and almost 30 % of patients who suffer from it do not get control with classic antiepileptic drugs.  Objective: to characterize prescription patterns of new antiepileptic drugs in Camagüey municipality.  Methods: a descriptive and cross-section study about use of medicines, of prescription-indication type with elements of therapeutic scheme was conducted. The study universe was composed of 300 patients and all of them were included in the research. The following variables were studied: group of age, indications, associations and interval of administration.  Results: the use of vigabatrin and lamotrigin prevailed in children and patients with diagnosis of epilepsy while the Gabapentin was more frequent used in adults and neuropathic pain. Vigabatrin and lamotrigin were mainly used in associations with classical antiepileptic drugs, being valproic acid the most used drug on it. Gabapentin was used alone. There were mistakes on intervals of administration of all studied drugs.  Conclusions: the prescription of new antiepileptic drugs was adequate in most cases. Identified mistakes were related to intervals of administration.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[PRESCRIPCIONES DE MEDICAMENTOS]]></kwd>
<kwd lng="es"><![CDATA[CONVULSIONES]]></kwd>
<kwd lng="es"><![CDATA[ANTICONVULSIVANTES]]></kwd>
<kwd lng="es"><![CDATA[ENFERMEDADES DEL SISTEMA NERVIOSO]]></kwd>
<kwd lng="es"><![CDATA[EPIDEMIOLOGÍA DESCRIPTIVA]]></kwd>
<kwd lng="en"><![CDATA[DRUG PRESCRIPTIONS]]></kwd>
<kwd lng="en"><![CDATA[SEIZURES]]></kwd>
<kwd lng="en"><![CDATA[ANTICONVULSANTS]]></kwd>
<kwd lng="en"><![CDATA[NERVOUS SYSTEM DISEASES]]></kwd>
<kwd lng="en"><![CDATA[EPIDEMIOLOGY, DESCRIPTIVE]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín Zurro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Atención primaria. Problemas de salud en la consulta de medicina de familia]]></source>
<year>2014</year>
<edition>7a</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier S.L.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado de Medicina interna.]]></source>
<year>2016</year>
<edition>25a</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier S. L]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daroff]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mazziotta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pomeroy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Bradley's Neurology in Clinical Practice]]></source>
<year>2016</year>
<edition>7a</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikati]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizures in Childhood]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hani]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kliegman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Station]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[St Geme]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schor]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Nelson Textbook of Pediatrics]]></source>
<year>2016</year>
<edition>20 th</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier, Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia Álvarez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epilepsia de difícil control en Pediatría. Nuevas drogas antiepilépticas]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Abadal Borges]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2005</year>
<volume>77</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa Sánchez]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epilepsia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vicente Peña]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Porto]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Zulueta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana López]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Riverón González]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ledo Grogués]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnóstico y tratamiento en Medicina Interna]]></source>
<year>2012</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rimbau Cabrera]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Patrón de reacciones adversas a los anticonvulsivantes en niños en la provincia de Camagüey]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Camagüey ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farreras Valentí]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rozman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina Interna]]></source>
<year>2012</year>
<edition>17</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier, S. L]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kros]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlling Cerebellar Output to Treat Refractory Epilepsy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Eelkman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[De Zeeuw]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hoebeek]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends in Neurosciences]]></source>
<year>2015</year>
<volume>38</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auvin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiepilépticos]]></article-title>
<source><![CDATA[EMC-Pediatría]]></source>
<year>2014</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez Betancur]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la epilepsia. Programa de Formación Médica Continuada Acreditado]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Vilaplana Domínguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sancho Rieger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>11</volume>
<numero>73</numero>
<issue>73</issue>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pozo Lauzán]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiepilépticos de tercera generación]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pozo Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2010</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pozo Alonso]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con medicamentos antiepilépticos en el niño]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pozo Lauzán]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2013</year>
<volume>85</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Cuadro básico de Medicamentos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Cuadro básico de Medicamentos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<edition>4ta</edition>
<page-range>71-91</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trevathan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kerls]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Hammer]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Vuong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Messenheimer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatrics]]></source>
<year>2006</year>
<volume>118</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brain MRI findings with vigabatrin therapy: case report and literature review]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chazen]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Imaging]]></source>
<year>2016</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos analgésicos no opioides]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Fleisher]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiener-Kronish]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<source><![CDATA[Miller. Anestesia]]></source>
<year>2016</year>
<page-range>1-17</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier, S.L.U]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caminero Rodríguez]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dolor neuropático y neuralgias craneofaciales.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Serra Catafau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado de dolor neuropático]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacoterapia de las epilepsias]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Brunton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chabner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Knollmann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Goodman y Gilman. Las bases farmacológicas de la terapéutica]]></source>
<year>2012</year>
<edition>12a</edition>
<page-range>583-606</page-range><publisher-loc><![CDATA[México D.F ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales Plaza]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones de prescripción de antiepilépticos en pacientes colombianos afiliados al Sistema General de Seguridad Social en Salud]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Machado Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurología]]></source>
<year>2014</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vigabatrin versus carbamazepine monotherapy for epilepsy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2015</year>
<volume>11</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marson]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Kharusi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Alwaidh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Appleton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Chadwick]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>369</volume>
<numero>9566</numero>
<issue>9566</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kälviäinen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yurkewicz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Weaver]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Knapp]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Neurol]]></source>
<year>2011</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[QY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[RQ]]></given-names>
</name>
<name>
<surname><![CDATA[Bao]]></surname>
<given-names><![CDATA[YX]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[RY]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia Álvarez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la vigabatrina en la epilepsia refractaria del niño]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Garnelo Loaeza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonet Quesada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Odales Ibarra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero Martínez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2007</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armijo Simon]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos antiepilépticos y anticonvulsivantes]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Herranz Fernández]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Flórez Beledo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Armijo Simon]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Mediavilla Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacología Humana]]></source>
<year>2014</year>
<edition>6ta</edition>
<page-range>476-502</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Umemura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2016</year>
<volume>72</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>3</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
